Hybrid-Core Tech Speeds Next-Generation Genomic Sequencing Analysis Pipeline
|
By LabMedica International staff writers Posted on 05 Mar 2013 |
A new hybrid-core system increases genomic application performance with lower ownership costs.
Convey Computer (Richardson, TX, USA) announced that the Broad Institute (Cambridge, MA, USA) has installed a Convey HC-2 system as part of their high performance compute farm. The Broad Institute) plans to use the system to speed their genomic pipelines and slash their overall cost of analysis. The Broad Institute is one of the leading biomedical and genomic research centers, generating terabases of sequence data per day.
Convey is working closely with the Broad as they incorporate the Convey system into their pipeline. “We are pleased that the Broad has selected Convey to accelerate critical portions of their next-generation sequencing analysis pipeline,” explained Dr. George Vacek, Director of Convey Computer’s Life Sciences business unit. “Broad is a leader in the adoption of new sequencing technology and in development of corresponding analysis methods. Our ongoing relationship to optimize their analysis tools will have a high impact on researchers worldwide.”
The Broad Institute purchased the Convey system to explore how the hybrid-core computer could accelerate their pipelines while reducing costs. “Although BWA is not a large part of the overall pipeline wall time, in terms of CPU dollars spent it is a very large component,” explained Tim Fennell, director of informatics for the Broad’s genomics platform. “With the Convey system, we expect to increase performance of BWA 10-fold. The Convey system will allow us to increase our efficiency and complete more analysis per dollar.” (The Burrows-Wheeler Aligner [BWA] is an efficient program that aligns comparatively short nucleotide sequences against a long reference sequence such as the human genome.)
Installation of the Convey system at the Broad was quick and easy. “Installing the Convey system was just like installing any other piece of compute hardware. It required no customization at all, fitting naturally into our existing infrastructure,” said Eric Jones, manager of research computing. “Additionally, I’m impressed with Convey’s customer support; I can quickly and easily talk to knowledgeable people.”
Convey’s hybrid-core architecture pairs classic Intel x86 microprocessors with a coprocessor comprised of FPGAs. Particular algorithms—BWA-based alignment, for example—are optimized and translated into code that is loadable onto the coprocessor at runtime. The systems help customers dramatically increase performance over industry standard servers while reducing energy costs associated with high-performance computing.
The world’s first hybrid-core computer, the Convey Computer’s system, combines the low cost and simple programming model of a commodity system with the performance of personalized hardware architecture. Using the Convey hybrid-core systems, users worldwide in industries such as life sciences, research, sophisticated analytics, and the government/defense are appreciating increased application performance and lower costs of ownership.
Related Links:
Convey Computer
Broad Institute
Convey Computer (Richardson, TX, USA) announced that the Broad Institute (Cambridge, MA, USA) has installed a Convey HC-2 system as part of their high performance compute farm. The Broad Institute) plans to use the system to speed their genomic pipelines and slash their overall cost of analysis. The Broad Institute is one of the leading biomedical and genomic research centers, generating terabases of sequence data per day.
Convey is working closely with the Broad as they incorporate the Convey system into their pipeline. “We are pleased that the Broad has selected Convey to accelerate critical portions of their next-generation sequencing analysis pipeline,” explained Dr. George Vacek, Director of Convey Computer’s Life Sciences business unit. “Broad is a leader in the adoption of new sequencing technology and in development of corresponding analysis methods. Our ongoing relationship to optimize their analysis tools will have a high impact on researchers worldwide.”
The Broad Institute purchased the Convey system to explore how the hybrid-core computer could accelerate their pipelines while reducing costs. “Although BWA is not a large part of the overall pipeline wall time, in terms of CPU dollars spent it is a very large component,” explained Tim Fennell, director of informatics for the Broad’s genomics platform. “With the Convey system, we expect to increase performance of BWA 10-fold. The Convey system will allow us to increase our efficiency and complete more analysis per dollar.” (The Burrows-Wheeler Aligner [BWA] is an efficient program that aligns comparatively short nucleotide sequences against a long reference sequence such as the human genome.)
Installation of the Convey system at the Broad was quick and easy. “Installing the Convey system was just like installing any other piece of compute hardware. It required no customization at all, fitting naturally into our existing infrastructure,” said Eric Jones, manager of research computing. “Additionally, I’m impressed with Convey’s customer support; I can quickly and easily talk to knowledgeable people.”
Convey’s hybrid-core architecture pairs classic Intel x86 microprocessors with a coprocessor comprised of FPGAs. Particular algorithms—BWA-based alignment, for example—are optimized and translated into code that is loadable onto the coprocessor at runtime. The systems help customers dramatically increase performance over industry standard servers while reducing energy costs associated with high-performance computing.
The world’s first hybrid-core computer, the Convey Computer’s system, combines the low cost and simple programming model of a commodity system with the performance of personalized hardware architecture. Using the Convey hybrid-core systems, users worldwide in industries such as life sciences, research, sophisticated analytics, and the government/defense are appreciating increased application performance and lower costs of ownership.
Related Links:
Convey Computer
Broad Institute
Latest BioResearch News
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
Simple One-Hour Saliva Test Detects Common Cancers
Early detection is critical for improving cancer outcomes, yet many diagnostic tests rely on invasive procedures such as blood draws or biopsies. Researchers are exploring simpler approaches that could... Read more
Blood Test Could Help Guide Treatment Decisions in Germ Cell Tumors
Chemotherapy is often highly effective for germ cell tumors, but in a subset of patients, the disease does not respond well to standard treatment. For these individuals, doctors may consider high-dose... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







